{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-092414","form_type":"8-K","ticker":null,"cik":"0001309057","company_name":"China Health Industries Holdings, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.575132+00:00","generated_at":"2026-06-07T18:36:15.861202+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"China Health Industries closes acquisition of HempCan for ~$40.9M","bullets":["Closed acquisition of 100% of Heilongjiang HempCan Pharmaceuticals on Dec 1, 2023.","Total cash consideration of RMB295M (~$40.9M) paid to sellers Xin Sun and Kai Sun.","Transaction was previously announced in Form 8-K filed July 3, 2023.","Humankind, a wholly owned subsidiary, is the acquiring entity."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-092414","json":"https://secwatch.observer/filing/0001213900-23-092414.json","markdown":"https://secwatch.observer/filing/0001213900-23-092414.md","text":"https://secwatch.observer/filing/0001213900-23-092414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1309057/000121390023092414/0001213900-23-092414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1309057/000121390023092414/ea189444-8k_chinahealth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:36:15.861202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a54bfb4ba1b76bb64571f8e9609f3fddc3591eff","claim":"China Health Industries Holdings, Inc. completed an acquisition involving Mr. Xin Sun and Mr. Kai Sun for RMB295 million (approximately $40,916,530) (closed 2023-12-01).","evidence_excerpt":"and the changes of business registration have been completed. As the consideration for the Acquisition, the Company paid the Sellers an aggregate cash consideration of RMB295 million (approximately $40,916,530) in exchange for 100% equity ownership of HempCan. The English translation of the Agreements are filed herein as Exhibit 10.1 and Exhibit 10.2 and","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1309057/000121390023092414/0001213900-23-092414-index.htm","confidence":1.0,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Mr. Xin Sun and Mr. Kai Sun"},{"label":"Consideration","value":"RMB295 million (approximately $40,916,530)"},{"label":"Closing","value":"2023-12-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}